Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis

Metabolism: Clinical and Experimental

Volumn 47, Issue 9, 1998, Pages 1058-1064

  Banyai, S ^a   Streicher, J ^b   Strobl, W ^b   Gabriel, H ^b   Gottsauner Wolf, M ^b   Rohac, M ^b   Weidinger, F ^b   Horl W H ^b   Derfler, K ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

APHERESIS; ARTICLE; BLOOD CLOT LYSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIETARY INTAKE; FAMILIAL HYPERLIPEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031753653     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90278-5     Document Type: Article

References (62)

1. Dahlen GH: Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 108:111-126, 1994
2. Utermann G: The mysteries of lipoprotein (a). Science 246:904-910, 1989
3. Armstrong VW, Cremer P, Eberle E, et al: The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 62:249-257, 1986
4. Kostner GM, Krempler F: Lipoprotein (a). Curr Opin Lipidol 3:279-284, 1992
5. Kamboh MI, Evans RW, Aston CE: Genetic effect of apolipoprotein (a) and apolipoprotein E polymorphism on plasma quantitative risk factors for coronary heart disease in American black women. Atherosclerosis 117:73-81, 1995
6. Marcovina SM, Morrisett JD: Structure and metabolism of lipoprotein (a). Curr Opin Lipidol 6:136-145, 1995
7. Kontula K, Ehnholm CH: Regulatory mutations in human lipoprotein disorders and atherosclerosis. Curr Opin Lipidol 7:64-68, 1996
8. Utermann G, Haibach C, Trommsdorff M, et al: Genetic architecture of the atherogenic lipoprotein (a). Ann NY Acad Sci 748:301-312, 1995
9. Maher VMG, Brown BG: Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol 6:229-235, 1995
10. Chapmann MJ, Huby T, Nigon F, et al: Lipoprotein (a): Implications in atherothrombosis. Atherosclerosis 110:S69-S75, 1994 (suppl)
11. Budde T, Fechtrup C, Bösenberg E, et al: Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 14:1730-1736, 1994
12. Durrington PN, Ishola M, Hunt L, et al: Apolipoprotein (a), AI and B and parental history in men with early onset ischemic heart disease. Lancet 1:1070-1073, 1988
13. Seed M, Hopplicher F, Reaveley D, et al: Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Eng J Med 322:1494-1499, 1990
14. Cremer P, Nagel D, Labrot B, et al: Lipoprotein Lp(a) as predictor of myocardial infarction in comparison fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 24:444-453, 1994
15. Schaefer EJ, Lamon-Fava S, Lenner JL, et al: Lipoprotein (a) levels and risk of coronary heart disease in men. JAMA 271:999-1003, 1994
16. Sandkamp M, Funke H, Schulte H, et al: Lipoprotein (a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 36:20-23, 1990
17. Scanu AM: Lipoprotein (a): A genetic risk factor for premature coronary heart disease. JAMA 267:3326-3329, 1992
18. Mbewu AD, Durrington PN: Lipoprotein (a): Structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 85:1-14, 1990
19. Carmena R, Lussier-Cacan S, Roy M, et al: Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect. Arterioscler Thromb Vasc Biol 16:129-136, 1996
20. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA 270:2195-2199, 1993
21. Farrer M, Game FL, Albers CJ, et al: Coronary artery disease is associated with increased lipoprotein (a) concentrations independent of the size of circulating apolipoprotein (a) isoforms. Arterioscler Thromb 14:1272-1283, 1994
22. Bowden JF, Pritchard PH, Frohlich JJ: Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary disease in familial hypercholesterolemia. Arterioscler Thromb 14:1561-1568, 1994
23. Kronenberg F, Kathrein H, König P, et al: Apolipoprotein (a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14:1405-1411, 1994
24. Islam S, Gutin B, Smith C, et al: Association of apolipoprotein (a) phenotypes in children with family history of premature coronary artery disease. Arterioscler Thromb 14:1609-1616, 1994
25. Marcovina SM, Zhang ZH, Gaur VP, et al: Identification of 34 apolipoprotein (a) isoforms: differential expression of apolipoprotein (a) alleles between American blacks and whites. Biochem Biophys Res Commun 191:1192-1196, 1993
26. Lackner C, Cohen JC, Hobbs HH: Molecular definition of the extreme size polymorphism in apolipoprotein (a). Hum Mol Genet 2:933-940, 1993
27. Mbewu AD, Durrington PN, Mackness MI, et al: Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. Br Heart J 71:316-321, 1994
28. Smith EB, Cochran S: Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) [Lp(a)]. Atherosclerosis 84:173-181, 1990
29. Bottalico LA, Keesler GA, Fless GM, et al: Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein (a) and apoprotein (a) internalization and degradation. J Biol Chem 268:8569-8573, 1993
30. Trieu VN, Zioncheck TF, Lawn RM, et al: Interaction of apolipoprotein (a) with apolipoprotein B-containing lipoproteins. J Biol Chem 266:5480-5485, 1991
31. Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al: Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 260:1655-1658, 1993
32. Smith EB, Cochran S: Factors influencing the accumulation in fibrous plaques of lipid derived from low-density lipoprotein. Preferential immobilisation of lipoprotein (a) Lp(a). Atherosclerosis 84:173-181, 1990
33. Berglund L: Diet and drug therapy for lipoprotein (a). Curr Opin Lipidol 6:48-56, 1995
34. Seed M, O'Connor B, Perombelon N, et al: The effect of nicotinic acid and acipimox on lipoprotein (a) concentration and turnover. Atherosclerosis 101:61-68, 1993
35. Kazumi T, Yoshino G, Shima F, et al: Niceritrol-induced reductions in serum lipoprotein (a) continue for one year. Curr Ther Res Clin Exp 54:550-552, 1993
36. Kostner GM, Gavish D, Leopold B, et al: HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 80:1313-1319, 1989
37. Sirtori CR: New targets for lipid lowering and atherosclerosis prevention. Pharmacol Ther 67:433-447, 1995
38. Richter WO, Jacob BG, Ritter MM, et al: Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 42:888-894, 1993
39. Gruber C, Svoboda K, Pidlich J, et al: Reduction of lipoprotein(a) by immunospecific LDL apheresis, in Gotto AM Jr, Mancicni M, Richter WO, et al (eds): Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease. Basel, Switzerland, Karge, 1993, pp 219-222
40. Armstrong VW, Schleef J, Thiery J, et al: Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein (a): Kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 19:235-240, 1989
41. Schenck I, Keller C, Hailer E, et al: Reduction of Lp(a) by different methods of plasma exchange. Klin Wochenschr 66:1197-1201, 1988
42. Gordon BR, Kelsey SF, Bilheimer DW, et al: Treatment of refractory familial hypercholesterolemia by low density lipoprotein apheresis using an automated dextran sulphate cellulose absorption system. Am J Cardiol 70:1010-1016, 1992
43. Lasuncion MA, Teruel JL, Alvarez JJ, et al: Changes in lipoprotein (a), LDL-cholesterol and apolipoprotein B in homozygous familial hypercholesterolemic patients treated with dextran sulfate LDL apheresis. Eur J Clin Invest 23:819-826, 1993
44. Jansen M, Gabriel H, Banyai S, et al: Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient. Wien Klin Wochensch 108:425-431, 1996
45. Pokrovsky SN, Sussekov AV, Afanasieva OI, et al: Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) [Lp(a)] apheresis: Preliminary clinical data. Chem Phys Lipids 67:323-330, 1994
46. Daida H, Lee YJ, Yokoi H, et al: Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Am J Cardiol 73:1037-1040, 1994
47. Bambauer R, Schiel R, Keller HE, et al: Low-density lipoprotein apheresis in the treatment of two patients with coronary heart disease and extremely elevated lipoprotein (a) levels. Artif Organs 20:340-343, 1996
48. Fadul JEM, Vessby B, Wikström B, et al: Treatment of homozygous familial hypercholesterolemia with low density lipoprotein apheresis: A 4 year follow-up study. Artif Organs 21:364-368, 1997
49. Angelin B: Therapy for lowering lipoprotein (a) levels. Curr Opin Lipidol 8:337-341, 1997
50. The Expert Panel report of the National Cholesterol Education Program Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 148:36-49, 1988
51. Kaplan AA, Halley SE, Reardon J, et al: One year's experience using a rotating filter for therapeutic plasma exchange. ASIO Transact 35:262-264, 1989
52. Svoboda K, Derfler K, Koppensteiner R, et al: Extracorporal lipid elemination for treatment of gestational hyperlipidemic pancreatitis. Gastroenterology 104:1527-1531, 1993
53. Derfler K, Swoboda K, Hirschl MM, et al: Comparison of plasmaseparation and immunospecific LDL-elimination in severe hyper-cholesterolemia. Int J Artif Organs 15:307-308, 1992
54. Kroon AA, Aengevaeren WRM, van der Werf T, et al: LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary athero-sclerosis. Circulation 93:1826-1835, 1996
55. Kroon AA, vanAsten WNJC, Stahlenhoef AFH: Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 125:945-954, 1996
56. Kostner GM, Gavish D, Leopold F, et al: HMG-CoA reductase inhibitors lower LDL but increase Lp(a) levels: A study of 24 individuals treated with simvastatin or lovastatin. Circulation 80:1313-1319, 1989
57. Jürgens G, Ashy A, Zenker G: Raised serum lipoprotein (a) during treatment with lovastatin. Lancet 1:911-912, 1989
58. Thompson GR, Maher WMG, Matthews S, et al: Familial Hypercholesterolemia Regression Study: A randomised trial of low-density-lipoprotein apheresis. Lancet 345:811-816, 1995
59. Pfohl M, Naoumova RP, Klass C, et al: Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res 35:1946-1955, 1994
60. Koizumi J, Koizumi I, Uno Y, et al: Reduction of lipoprotein(a) by LDL-apheresis using dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 100:65-74, 1993
61. Hearn JA, Donohue BC, Ba'albaki H, et al: Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 69:736-739, 1992
62. Maca T, Ahmadi R, Derfler K, et al: Elevated lipoprotein (a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? Atherosclerosis 127:27-34, 1996